Institut AllergoSan: Managing Director on a health mission
Institut AllergoSan, including its brand OMNi-BiOTiC®, is continuously growing - not only in sales figures but also in manpower:
By hiring Mag. Thomas Perissutti, Institut AllergoSan found a highly-qualified Managing Director to play a decisive role in shaping a positive future for the company with his experience and expertise.
The former board member of Neuroth AG looks forward to his new assignment: "My personal motivation is to help people and improve their quality of life. That is why I am exceptionally proud to now be a part of Institut AllergoSan: As a centre of expertise in microbiome research, we play a pioneering role when it comes to medical research which, in turn, improves the health foundation of every individual."
Company founder and CEO, Mag. Anita Frauwallner is pleased about the competent support: "Thomas Perissutti not only convinced my son and me with his expertise but also with his personality - we both have a good "gut feeling" and know that together, we can forge ahead with our mission: By continuously improving many fields in medicine with the help of medically relevant probiotics, and by making a significant contribution to the wellbeing of every single person."
OMNi-BiOTiC again Germany's No 1 OTC Brand
Institut AllergoSan - awarded several times in Austria and Germany
Institut Allergosan was again able to shine at this year's inspirato Pharma Marketing Award: the Graz-based family business convinced the jury with its multi-award winning successful brand OMNi-BiOTiC® and secured its second victory in the category "OTC Brand of the Year". In addition, Institut Allergosan took the second place in the "OTC Company of the Year" category. But that's not all: at the same time the IQVIA Awards ceremony took place in Vienna, where Institut AllergoSan also achieved a top ranking. This is clear evidence of the increasing importance of medically relevant and indication-specific synbiotics.
Yesterday, the inspirato Pharma Marketing Award was presented for the sixth time as part of the industry meeting “Pharma Marketing” in Bonn, Germany. The award honors the most successful OTC companies, brands and new launches of the year. Institut Allergosan was pleased with the victory by its successful synbiotics brand OMNi-BiOTiC® in the category "OTC Brand of the Year" - and this for the second time in a row. There was even more reason to celebrate with the second place in the category "OTC company of the year". The inspirato Pharma Marketing Award is based on the company's sales growth in 2017 as well as figures from the market research company Insight Health. In addition, the results of an online pharmacist survey are included in the evaluation. The final winners were selected by a jury consisting of industry representatives, agencies, consultants and retailers.
An outstanding award
The award also proves that the research and production of medically relevant, indication-specific synbiotics is playing an increasingly important role. "The ecosystem in our gut is so complex that we need different solutions for different clinical requirements. With our research work, we set new standards in the field of microbiome research and product development, "says Mag. Anita Frauwallner, founder and CEO of the Institut Allergosan. The secret behind the success of OMNi-BiOTiC®: the passion to develop products that set new standards in quality and that do not only treat symptoms, but also target the cause of the disease. This results in synbiotics that have a noticeable effect on the user and thus also trigger enthusiasm among people using OMNi-BiOTiC products.
A "Victor" for the best
At the same time, the IQVIA Awards event was held at the 25hours Hotel in Vienna. For the first time, IQVIA, a global leader in human data science, awarded the Pharma Excellence Award "Victor. For this award a rating was used which was based on market share, growth, focus market, innovation and brand as well as product diversity. "In addition to being awarded the OTC Brand of the Year in Germany, we also achieved a top ranking in Austria in the new IQVIA Pharma Excellence Award. This confirms the path we have taken to ensure that the highest quality and innovation-oriented research work prevails on the market, "concludes Anita Frauwallner.
Probiotic therapy of liver function disorders with OMNi-BiOTiC® HETOX
Europe’s most innovative OTC-product comes from Austria
Sensational success for Institut Allergosan from Graz, Austria: The probiotic OMNi-BiOTiC® HETOX* was awarded the international Nicholas Hall Award as the Europe-wide OTC innovation of the year 2016.
30% of the population already suffer from liver problems and contrary to the popular belief that alcohol is the predominant cause of liver damage, the number of patients with non-alcoholic fatty liver disease is rising drastically. Consuming sugar, fat, numerous pharmaceuticals, but also being infected by various viruses can impair the function of our detoxification centre, the liver – and frighteningly often this leads to liver cancer.
Using a probiotic which was developed by Institut Allergosan from Graz (OMNi-BiOTiC® HETOX), a team from the Medical University of Graz under the supervision of Prof Vanessa Stadlbauer-Köllner could clearly show that several special gut bacteria influence liver function and the severity of infections. “During this placebo controlled study the liver function of the patients taking the probiotic improved significantly”, summarises Stadlbauer-Köllner.
International recognition for the cooperation in Graz
Hepatologists from around the world have showed great interest in the study: The study was presented at the renowned “Liver Week”, organised by the American Association for the Study of Liver Diseases (AASLD). Amongst the 10,000 submitted studies it was awarded the title “poster of distinction”.
Now the product has been awarded the renowned Nicholas Hall OTC Marketing Award for the Europe-wide OTC innovation of the year 2016: “This is a particularly great honour and a massive achievement for us” rejoices Mag. Anita Frauwallner, CEO of Institut Allergosan. “The fact that our product OMNi-BiOTiC® HETOX has received such praise concerning the therapy of liver diseases not only highlights the increasing importance of relevant probiotics. It is even more pleasing to see the international recognition our company is receiving; a company which has employed itself to studying the gut and its microbiome for 25 years. We have already shown on multiple occasions that gut bacteria positively influence the entire organism.”
Cornerstone ceremony of the internationally successful Institut Allergosan
One of Styria’s figureheads, the company Institut Allergosan, is building a dazzling new headquarters in Graz, Austria
This impressive flagship of the pharmaceutical company Institut Allergosan is emerging in the south of Styria’s capital and will stretch over an area of just under 12,500 square metres. On Thursday, the founder, and CEO Mag. Anita Frauwallner celebrated laying the foundation stone together with the mayor of Graz, Mag. Siegfried Nagl.
Personally, as well as in business matters, Anita Frauwallner is a devout Styrian and she proves this through her renewed commitment to this location. “Although Institut Allergosan is an internationally active company, our roots clearly lie in the heart of Styria. It was here that we developed our ideas and visions; it is here that we will continue our research.” Even a large portion of the over 100 employees, the people who made the probiotic specialist one of Austria’s top pharmaceutical companies, are from Styria.
In fact, the company has become so big that there just wasn’t enough space in their old location in Graz. Every year, the company’s revenue has grown in double-digits. “We started out as a single employee in 2002; meanwhile our team has grown to 115 employees”, explains Frauwallner. “We want to be able to offer our employees an inspiring work environment, that matches their exceptional dedication.”
Starting with the building’s completion in autumn 2017, the employees will have access to the 6430 square metres of usable area which the 5-storey building will offer. There is a particular focus on the event centre, which will include a lecture hall for up to 260 people. Moreover, there will be seminar rooms and encounter zones on every floor.
The mayor of Graz, Siegfried Nagl, is also very pleased by the company’s plans for a new headquarters. “With their research and products, Anita Frauwallner and Institut Allergosan ensure that nothing can upset one’s stomach too easily! Her ideas and innovations have an international impact, but ultimately, they ensure a workplace for many people in Graz.”
Focus: Sustainability and theme-relevant architecture
The construction concept was drawn up by the East-Styrian planning department Architektur 64. The plan pays special attention to the greening of the roof and facade elements, as well as incorporating photovoltaic installations on the roof; these will deliver a substantial amount of the building’s energy demands. This reflects the sustainability of the company’s philosophy. Moreover, the architects didn’t forget Institut Allergosan’s central topic of interest: A highlight of the design is a coiled main staircase located in the foyer. It is a three-dimensional representation of the institute’s main research field, the gut.
“This house we are building, shouldn’t only be used for work. For many, it will be a house of health”, says Frauwallner. The new location will not only continue to be the development site for solutions to health issues. It will offer the possibility for visitors to experience lectures from renowned physicians and researchers. “In these rooms, people should obtain inspiration on how to live long and healthy lives”, says Frauwallner.
Relief for the liver – from the gut
Probiotic from Austrian research is a beacon of hope for people suffering from liver disease
More and more people suffer from liver diseases, especially the feared liver cirrhosis. For many patients this diagnosis means the beginning of a race against time, because at some point the damage to the liver is no longer reversible. Yet a dedicated cooperation between the Medical University of Graz and the competence centre for microbiome research at the institute Allergosan has achieved a breakthrough: A probiotic proves to be a beacon of hope for people suffering from liver disease.
30 % of the population already suffer from liver problems. Contrary to the popular belief that liver damage is primarily caused by alcohol, the number of patients suffering from non-alcoholic fatty liver disease is increasing at an alarming rate. Various viral diseases, but especially an excessive consumption of sugar, fat and numerous pharmaceuticals, can severely inhibit the function of our body’s detoxification centre.
What many people don’t realise is that the gut plays a key role in our liver’s health! A balanced intestinal flora and intact intestinal barrier are able to eliminate pathogens and toxic substances beforehand and so unburden the liver. However, if the intestinal mucosa is damaged (“leaky gut”), an increased amount of harmful substances can enter the blood steam via the portal vein. This blood vessel leads directly to the liver and so the liver is flooded with pathogenic substances. This overburdens the liver, causing blood congestion, hardening and often it can no longer fulfil its functions completely.
A cooperation in Graz: A probiotic improves liver function
Associate professor Vanessa Stadlbauer-Köllner’s team from the Medical University of Graz, tested a probiotic (OMNi-BiOTiC® HETOX*) developed by the institute Allergosan from Graz. With these results it could be shown for the first time ever, that extremely small gut bacteria can have a really big influence on liver function.
It was a placebo controlled, double blind study. 101 patients with liver cirrhosis, which were already being treated at the Graz university hospital’s department for gastroenterology and hepatology, were included in the study. Every day, for over the six months, the patients either took the specially developed probiotic or a placebo. Afterwards they were observed closely for another six months. “In this placebo controlled study, the liver function of those who took the probiotic improved significantly”, summarises professor Stadlbauer-Köllner.
Patients with liver cirrhosis generally exhibit increased susceptibility to infections. This makes it even more significant that parameters such as neopterin and respiratory burst, which are closely associated with increased immune activity, show a significantly positive trend under influence of the probiotic. This would also explain the lower infection rate during therapy in the group treated with the probiotic (15 vs 29 in the placebo group).
The tolerability of OMNi-BiOTiC® HETOX and the therapy adherence (98,9% of the doses were taken) were excellent in the probiotic group. In addition, no interactions with other medications were documented, which is especially important when treating high-risk patients such as these. It’s also interesting to note that only one patient from the probiotic group dropped out of the study before it was over, whereas there were 11 drop-outs in the placebo group. “That is notable evidence of an improved quality of life through the probiotic. The patients also claimed that they feel much more energetic and have more social contacts”, said Vanessa Stadlbauer-Köllner.
Mag. Anita Frauwallner, CEO and research director of the institute Allergosan: “The outstanding results of this study are trendsetting for modern medicine, in which microbiome research already plays a definitive role. It’s yet another milestone in our 25 years of work.”
So far there have not been any therapeutic intervention options which could improve liver function in patients with liver cirrhosis. This study from Graz however, clearly shows that with the application of specially developed probiotics such as OMNi-BiOTiC® HETOX, an improvement of liver function is suddenly achievable. The international interest is immense: The study data was presented at the world’s largest hepatology congress, the renowned “Liver Week”, which is organised by the American Association for the Study of Liver Diseases (AASLD). Among the 10,000 submitted works, it was awarded the title “poster of distinction”.
Anita Frauwallner: “We were able to show that OMNi-BiOTiC® HETOX can contribute a large amount towards a healthy liver. On the one hand it targets the root of the problem, and more importantly, none of the serious side effects caused by medication ever arise during the application of probiotics. A crucial step towards a healthy future.”